Fraud: Do as I say, not as I do

Despite the fact that he appears to have fabricated at least half of the patients in a 2005 linkurl:Lancet study;http://www.the-scientist.com/news/display/22952/ , Norwegian researcher Jon Sudbo has an opinion on the ethics of 'rigorously conducted clinical trials' ? or at least he did in 2001. The results of such trials, he wrote in a letter to the New England Journal of Medicine ? which is now investigating his work published there ? 'make up the foundation for what we like to term 'evidence-b

Written byIvan Oransky
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Despite the fact that he appears to have fabricated at least half of the patients in a 2005 linkurl:Lancet study;http://www.the-scientist.com/news/display/22952/ , Norwegian researcher Jon Sudbo has an opinion on the ethics of 'rigorously conducted clinical trials' ? or at least he did in 2001. The results of such trials, he wrote in a letter to the New England Journal of Medicine ? which is now investigating his work published there ? 'make up the foundation for what we like to term 'evidence-based medicine.'' Because less than 1% of patients who take part in trials are elderly, he continues, 'the 'evidence' on which we base our future treatment may not apply to most of the patients we will serve in the future ? the growing population of elderly persons. Consequently, physicians may decide not to offer a treatment because the evidence does not support its use in clinical circumstances such as advanced age. This matter, too, merits ethical consideration.' The other option, of course, is just fabricating research subjects so the results can be more easily generalized.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies